Fertilization is an essential biological process in sexual reproduction and comprises a series of molecular interactions between the sperm and egg 1, 2 . The fusion of the haploid spermatozoon and oocyte is the culminating event in mammalian fertilization, enabling the creation of a new, genetically distinct diploid organism 3,4 . The merger of two gametes is achieved through a two-step mechanism in which the sperm protein IZUMO1 on the equatorial segment of the acrosome-reacted sperm recognizes its receptor, JUNO, on the egg surface [4] [5] [6] . This recognition is followed by the fusion of the two plasma membranes. IZUMO1 and JUNO proteins are indispensable for fertilization, as constitutive knockdown of either protein results in mice that are healthy but infertile 5, 6 . Despite their central importance in reproductive medicine, the molecular architectures of these proteins and the details of their functional roles in fertilization are not known. Here we present the crystal structures of human IZUMO1 and JUNO in unbound and bound conformations. The human IZUMO1 structure exhibits a distinct boomerang shape and provides structural insights into the IZUMO family of proteins 7 . Human IZUMO1 forms a high-affinity complex with JUNO and undergoes a major conformational change within its N-terminal domain upon binding to the egg-surface receptor. Our results provide insights into the molecular basis of sperm-egg recognition, cross-species fertilization, and the barrier to polyspermy, thereby promising benefits for the rational development of non-hormonal contraceptives and fertility treatments for humans and other mammals.
. Human IZUMO1 forms a high-affinity complex with JUNO and undergoes a major conformational change within its N-terminal domain upon binding to the egg-surface receptor. Our results provide insights into the molecular basis of sperm-egg recognition, cross-species fertilization, and the barrier to polyspermy, thereby promising benefits for the rational development of non-hormonal contraceptives and fertility treatments for humans and other mammals.
The journey of a human sperm to an egg ends in the female oviduct, where the active sperm penetrates through the zona pellucida glycoprotein layer of the egg to reach the perivitelline space between the zona layer and the plasma membrane of the oocyte [8] [9] [10] . The active sperm then fuses with the oocyte membrane to allow the formation of the zygote 1, 4 . At least two membrane-bound proteins, sperm IZUMO1 and egg JUNO, are essential for gamete recognition, fusion, or both 5, 6 . Both the IZUMO1 and JUNO (also known as IZUMO1R) genes are conserved in other mammals 6, 11 (Extended Data Figs 1, 2). Structural and biochemical studies of IZUMO1 are hampered by difficulties in recombinant protein expression 12 . Using Drosophila melanogaster S2 cells, we expressed and purified the extracellular region of human IZUMO1 (residues 22-254) by Ni 2+ -affinity and gel filtration chromatography. Biophysical characterization of IZUMO1 revealed a stable and monomeric protein with extensive mixed α -β secondary structural characteristics (Extended Data Fig. 3 ). We obtained crystals of unbound IZUMO1 and determined its structure at 3.1 Å resolution. IZUMO1 is a monomer and adopts a distinct boomerang shape with dimensions of around 85 Å × 25 Å × 22 Å. The overall structure consists of two domains: a rod-shaped N-terminal four-helix bundle (4HB; residues 22-134) and a C-terminal immunoglobulin-like (Ig-like; residues 167-254) domain ( Fig. 1 and Supplementary Fig. 1 ). Two anti-parallel β -strands (β 1 and β 2) function like a hinge between the 4HB and Ig-like domains.
The four helices in the IZUMO1 4HB domain (α1, α2, α3 and α4) vary from 14 to 30 residues in length. The helices have amphipathic character with a polar surface exposed to solvent and hydrophobic residues packing into a core. Helices α1-α2 and α3-α4 are connected with short five-residue loops (L1 and L3), and a longer 15-residue loop (L2) links α2 to α3. The 4HB and hinge regions are stabilized by an extensive network of disulfide linkages (C22-C149, C25-C152, C135-C159, and C139-C165) and charge-charge interactions (H44-D101, E80-K154, and R96-E110) that are conserved in almost all IZUMO1 orthologues and other IZUMO family proteins (Extended Data Fig. 1 and Supplementary Fig. 2 ).
The IZUMO1 Ig-like domain resides at the membrane-proximal end of the molecule. It adopts a seven-stranded (A, B, C, C′ , E, F, G) β -sandwich with the two β -sheets covalently linked with an Ig-superfamily (IgSF) conserved disulfide bond (C182-C233) between strands B and F (Fig. 1) . Seven-stranded Ig-like folds classically consist of a 3 + 4 arrangement with β -strands A, B and E forming β -sheet 1, and β -strands C, C′ , F and G forming β -sheet 2 (ref. 13 ) ( Supplementary  Fig. 3 ). The IZUMO1 Ig-like domain has a novel 2 + 5 organization representing a previously undescribed IgSF subtype. In IZUMO1 , strand A interacts with β -sheet 2 rather than β -sheet 1. The disulfide bond preceding β -strand A (C139-C165) may constrain the movement of the strand towards β -sheet 1 and thereby result in this strand switch (Supplementary Fig. 3 ). We also determined the crystal structure of a slightly longer IZUMO1 22-268 construct at 2.9 Å resolution to gain insights into the C-terminal linker region immediately following the Ig-like domain. The IZUMO1 22-268 structure superimposes well with IZUMO1 (root mean square deviation (r.m.s.d.) of 1.0 Å over all atoms) ( Supplementary Fig. 4 ). However, no electron density was observed after residue 256, suggesting that the linker region following the Ig-like domain is flexible.
JUNO (previously known as folate receptor-δ (FOLR-δ )) is a glycophosphatidylinositol (GPI)-anchored, cysteine-rich glycoprotein displayed on the egg surface that has been demonstrated to be the egg receptor of IZUMO1 (ref. 6). We determined the crystal structure of unbound JUNO 20-228 at 1.8 Å resolution. JUNO has a globular architecture that is composed of five short α -helices (α1, α2, α3, α4 and α5), three 3 10 helices and two short two-stranded antiparallel β -sheets ( Fig. 1 and Supplementary Fig. 1 ). Eight conserved disulfide bonds stabilize the core helices α1, α2, α3 and α4 and the flexible loops. JUNO shares sequence and structural similarity with human FOLR-α and FOLR-β (~ 58% sequence identity and ~ 1 Å r.m.s.d. over 197 Cα atoms) 14, 15 (Extended Data Fig. 4 ). Despite the close similarities, six key folate binding residues in FOLR-α and FOLR-β are not conserved in human JUNO, consistent with previous observations that JUNO does not bind folate 6, 14, 15 (Extended Data Fig. 4 ). While this manuscript was under revision, a partial structure of mouse JUNO was determined
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JUNO. The interaction is stable with a dissociation constant (K d ) of about 48-60 nM (Extended Data Fig. 3 ). In addition, IZUMO1 and JUNO co-purify as a 1:1 complex on size-exclusion chromatography. Our results indicate that these two proteins form a stable complex during the gamete fusion process. To understand the precise molecular interactions of IZUMO1 and JUNO, we determined the structure of the IZUMO1 22-254 -JUNO 20-228 complex at 2.4 Å resolution. In the asymmetric unit, we observed one IZUMO1 molecule binding to one JUNO molecule with an interface that spanned a surface area of about 910 Å 2 ( Fig. 2 and Extended Data Fig. 5 ). IZUMO1 has been shown to interact with JUNO via its N-terminal domain 17 . The crystal structure indicates that residues from all three IZUMO1 regions (4HB, hinge and Ig-like) contact JUNO through extensive non-bonded van der Waals, hydrophobic and aromatic interactions (more than 60% of total interface interactions; Extended Data Y   C27  C47   C55 C56  C79 C86   C95 C99   C132 C136   C143 C149  C166 C172  C186C206   250   JUNO  TM  1  254   Y   C22C25   C135 C139  C149C152   C159   C165   C182 C233   4HB  Hinge  Ig  CT  292 313 and JUNO are coloured as in Fig. 1 Letter reSeArCH bridges (K163 JUNO -E71 IZUMO1 and E45 JUNO -R160 IZUMO1 ) and eight hydrogen bond interactions at the interface ( Fig. 2 and Extended Data Fig. 5 ). However, all of these interactions are more than 3.0 Å apart, suggesting that they are weak.
Structural comparison of IZUMO1 and JUNO alone with their bound states revealed no major structural changes in JUNO or the Ig-like domain of IZUMO1 upon complex formation (Fig. 3) . A major conformational change was observed in the 4HB and hinge regions. All four helices in the 4HB region move about 20 Å towards JUNO upon binding, whereas the L2 and hinge regions shift by about 8 Å. As a result, bound IZUMO1 abandons its distinct boomerang shape and adopts an upright conformation. The structural constraints imposed by the short loops between the α1-α2 and α3-α4 helices allow the 4HB domain to translate as a single unit (Fig. 3) .
To understand the conformational dynamics of the IZUMO1-JUNO interaction in solution, we used a hybrid approach that combined small angle X-ray scattering (SAXS) and deuterium exchange mass spectrometry (DXMS). Ab initio SAXS reconstructions of unbound IZUMO1 revealed a distinct boomerang shape, similar to its crystal structure (Extended Data Fig. 6 ). When it binds JUNO 20-228 , IZUMO1 adopts an upright conformation. Our DXMS studies revealed that the residues lining the binding interface exhibited a reduced exchange profile in the complex compared to the unbound state (Fig. 4 , Extended Data Fig. 6 and Supplementary   Fig. 6 ). Moreover, DXMS experiments performed on IZUMO1 alone indicated a high level of exchange in the hinge region, suggesting dynamic flexible motion within this region. Upon binding JUNO, deuterium exchange of residues 127-140 of IZUMO1 in the hinge region was reduced by over 50%, which is greater than the reduction observed in residues at the IZUMO1-JUNO interface (Fig. 4) . The strong level of hydrogen/deuterium protection is due to the formation of 10 additional main-chain hydrogen bonds within residues 127-140 of the hinge region. This suggests that the IZUMO1 hinge region is stabilized in a 'locked' upright position in the presence of JUNO.
Mutational studies at the IZUMO1-JUNO interface revealed the structural determinants required for binding (Fig. 2 , Extended Data Table 1 and Supplementary Fig. 7 ). Upon binding to JUNO , a D72-Q130 hydrogen bond between IZUMO1 L2 and the 4HB α4 helix is disrupted to form a new intermolecular salt bridge (E71 IZUMO1 -K163 JUNO ) at the interface (Fig. 3) . Mutations of IZUMO1 D72 and Q130 to alanine did not affect binding to JUNO, as these residues are not involved at the interface. Alanine and charge-reversal mutations of the intermolecular E71 IZUMO1 -K163 JUNO salt bridge reduced the K d by approximately twofold, suggesting that this ion pair has a minor role in binding. Mutations to the R160 IZUMO1 -E45 JUNO intermolecular salt bridge result in a roughly 50-fold reduction in binding affinities, suggesting that this second electrostatic interaction has a major role in IZUMO1-JUNO recognition. Using SAXS, we characterized the binding mode of IZUMO1 and JUNO salt bridge mutants that hindered high-affinity complex formation. The SAXS scattering data and reconstructions of mutant complexes show no major changes compared to the wild-type IZUMO1-JUNO complex, and suggest proper complex formation despite up to 50-fold decrease in affinity (Extended Data Fig. 7 ). Notable reductions in binding (more than 20-fold) were also observed to result from mutations of IZUMO1 and JUNO residues that are conserved in most mammals (W148 IZUMO1 , H157 IZUMO1 , W62 JUNO and L81 JUNO ). In fact, a mutation of W148 IZUMO1 to alanine completely abolished IZUMO1-JUNO binding. These results agree well with the cell-oocyte binding assay presented in an accompanying crystal structure of the same complex 18 . Together, the results of our mutagenesis study suggest that the interface is probably stabilized through the combined effects of multiple van der Waals, hydrophobic, aromatic and electrostatic interactions. This allows the IZUMO1-JUNO interface to be resilient to mutations.
Although we observed discernible sequence conservation at the complex interface in both proteins, comparative sequence analysis revealed considerable variations among a number of interface residues. Approximately half of the residues (JUNO: Y44, E45, L58, F77, M83, R87, M145, Y147, K163; IZUMO1: L69, V141, K150, N151, K153, E155, A158, Y163, N239, S241) vary across mammalian species (Extended Data Figs 1, 2). Similar to the species-specific recognition employed Superposition of structures of unbound IZUMO1 and JUNO (shown in grey) on the IZUMO1 22-254 -JUNO 20-228 complex (coloured as in Fig. 1 ). Black arrows highlight the positional changes in secondary structure with the corresponding distances shown in angstroms. Inset, conformational changes within the L2 region during formation of the complex. The L2 region residue D72 and α 4 helix residue Q130 (both shown in grey) form a hydrogen bond in the unbound IZUMO1 structure. Upon binding to JUNO , the L2 region E71 (orange) forms an electrostatic interaction with JUNO 20-228 K163 (purple). Letter reSeArCH by glycoproteins in the zona pellucida that surrounds the egg, these residues may act to restrict productive IZUMO1 and JUNO binding to a specific pair of species 9, 19, 20 . For example, in primates, these residues are mainly preserved (Extended Data Figs 1, 2) , suggesting that the species-specific diversification of IZUMO1 and JUNO may be restricted to non-primate mammals.
Our structural characterizations indicate that human IZUMO1 does not have properties predictive of viral, intracellular or developmental fusogens, such as influenza A virus haemagglutinin (HA) and Caenorhabditis elegans epithelial fusion failure-1 (EFF-1) proteins [21] [22] [23] (Extended Data Fig. 8 ). This suggests that IZUMO1 does not function as a direct fusion protein. At least three different fusion mechanisms are possible (Extended Data Fig. 9 ). First, IZUMO1 may act as a scaffold to recruit a protein complex that contains or regulates other fusion proteins. The requirement of a multiprotein complex for fusion is not unusual, as some viruses, such as herpes simplex virus-1 or Epstein Barr virus, require the formation of a multicomponent fusion complex 24, 25 . Alternatively, Inoue et al. proposed that monomeric IZUMO1 on the sperm surface interacts with JUNO 26 and, subsequently, a protein disulfide isomerase facilitates the dimerization of IZUMO1 to allow it to interact with another oocyte receptor to facilitate fusion. Finally, the tight heterotypic interaction between human IZUMO1 and JUNO proteins may be sufficient to bring the sperm and egg membranes into close apposition and thereby lead to fusion. Regardless, the conformational changes within IZUMO1 suggest that receptor adhesion triggers the progression of the 4HB domain to the vicinity of the egg membrane and the conformational switch may be part of the structural changes required for fusion. After fusion, the fertilized egg rapidly sheds JUNO molecules into the perivitelline space 6 . Given our measured tight nanomolar affinities between IZUMO1 and JUNO, shed JUNO may essentially act as a rapid 'sperm-sink' to neutralize incoming acrosome-reacted sperm as an additional block to polyspermy. This process may be analogous to the shedding of viral glycoproteins (for example, Ebola virus shed and soluble glycoprotein), which can act as a decoy to absorb antibody responses 27, 28 .
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MethODS
No statistical methods were used to predetermine sample size. The experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment. Protein expression and purification. The genes encoding full-length human IZUMO1 (GenBank accession number: NM_182575, residues 1-350) and human JUNO (GenBank accession number: NM_001199206, residues 1-250) were codon optimized for expression in D. melanogaster and gene synthesized (Integrated DNA Technologies). The DNA sequences encoding the extracellular regions of IZUMO1 (residues 22-254 and 22-268) and JUNO (residues 20-228) with a BiP signal peptide were subcloned into a metallothionein promoter pMT expression vector (Invitrogen) modified with a puromycin selection marker (pMT-puro). All protein constructs contain a thrombin cleavage site and a 10 × His affinity tag at the C terminus. Binding interface mutants of IZUMO1 and JUNO were generated using a modified QuikChange PCR-based site-directed mutagenesis protocol. The resulting wild-type and mutant IZUMO1 22-254 , IZUMO1 and JUNO pMT-puro expression plasmids were stably transfected in Drosophila S2 cells (Invitrogen) using Effectene transfection reagent (Qiagen) according to the manufacturer's protocol. (S2 cells have been tested by Invitrogen for contamination of bacteria, yeast, mycoplasma and viruses, and been characterized by isozyme and karyotype analysis.) Briefly, Drosophila S2 cells were cultured in Schneider's medium (Lonza) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) plus 1× antibiotic-antimycotic (Gibco), and propagated at 27 °C. The day before transfection, 3 × 10 6 cells were seeded per well in a 6-well plate (Corning) with 3.0 ml complete growth medium and incubated overnight. On the day of transfection, 2 μ g expression plasmid was mixed with the transfection reagents and the transfection complexes were added drop-wise onto the S2 cells. At 72 h post-transfection, the cultured medium was replaced with fresh S2 growth medium supplemented with 6 μ g ml −1 puromycin (Bioshop). Subsequently, S2 cells were gradually adapted to FBS-free Insect-XPRESS growth media (Lonza) with 6 μ g ml −1 puromycin. Stably transfected cells were grown to 1 × 10 7 cells per ml in Insect-XPRESS growth medium using vented 2-l polycarbonate Erlenmeyer flasks (VWR) at 27 °C. Protein expression was induced with 500 μ M final concentration of sterile-filtered CuSO 4 . Cultured medium was collected 6-days after induction, clarified by centrifugation at 6750g for 20 min, concentrated and buffer exchanged into Ni-NTA binding buffer (20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 20 mM imidazole) using a Centramate tangential flow filtration system (Pall Corp.) All IZUMO1 and JUNO proteins were purified by Ni-NTA metal affinity chromatography. Eluted samples were buffer exchanged into TBS (10 mM Tris-HCl (pH 8.0), 150 mM NaCl) using a PD-10 desalting column (GE Life Sciences) and thrombin (EMD Millipore) digested at 22 °C for 24 h (1:2,000 (w/w) enzyme:protein ratio). The cleaved protein samples were then buffer exchanged to a low pH buffer (10 mM sodium acetate (pH 5.6), 150 mM NaCl) and enzymatically deglycosylated using 100 U endoglycosidase H (New England Biolabs) per mg of IZUMO1 or JUNO at 22 °C for 16 h. To prepare the IZUMO1-JUNO protein complexes, deglycosylated IZUMO1 and JUNO samples were mixed at a molar ratio of 1:1 and incubated at 22 °C for 2 h before size-exclusion chromatography on a custom prepgrade Superdex-200 XK 16/70 column equilibrated with TBS. Peak fractions were pooled and protein concentrations were quantified by measuring A 280 . Circular dichroism spectroscopy. Circular dichroism spectra of human IZUMO1 were acquired on a Jasco J-810 spectropolarimeter using a 1-mm quartz cuvette (Helma). Circular dichroism measurements were conducted with 50-100 μ M protein samples purified in 10 mM potassium phosphate (pH 7.5) and 150 mM NaCl buffer. Wavelength scans were recorded at 25 °C between 190 nm and 250 nm and averaged over five accumulations. Data were converted to mean residue ellipticity and secondary structure content was estimated using the K2D algorithm in the DichroWeb analysis server 29 . Thermal denaturation assays were performed at a wavelength of 222 nm by increasing the temperature from 20 °C to 99 °C and monitoring the change in ellipticity as a function of temperature. The data were baseline corrected with buffer blank, normalized between 0 (folded) and 1 (unfolded) and fit to a nonlinear biphasic sigmoidal curve using GraphPad Prism (GraphPad Software). Dynamic light scattering (DLS). IZUMO1 , JUNO , and IZUMO1 22-254 -JUNO 20-228 complex samples were prepared in TBS with 2% (v/v) glycerol and concentrated to 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0 and 5.0 mg ml −1 before the DLS measurements. DLS experiments were performed at 25 °C on a DynaPro Plate Reader II (Wyatt Technology). For each condition, 22 μ l of sample was loaded in triplicate onto a black 384-well clear-bottom plate (Greiner). Data acquisition was recorded over 5 s with a total of ten acquisitions for each concentration. The polydispersity and hydrodynamic radius (R H ) of the molecules in solution was calculated using Dynamics (v.7) software (Wyatt Technology).
Size exclusion chromatography-multiangle light scattering (SEC-MALS).
The oligomeric state of tag-removed, glycosylated IZUMO1 was assessed by multiangle light scattering. Monomeric bovine serum albumin (BSA) standard (2 mg ml −1 ; 66,432 Da) dissolved in PBS buffer (10 mM phosphate (pH 7.4), 2.7 mM KCl, 137 mM NaCl) was used to calibrate the MALS detectors. IZUMO1 was purified on an analytical Superdex-75 10/300 GL size exclusion column equilibrated in PBS buffer to ensure proper monodispersity. Then, 600 μ g IZUMO1 was applied onto a PBS-equilibrated Superdex-200 Increase 10/300 GL size exclusion column in-line with a Viscotek MALS detector (Malvern). The data were processed and weight-averaged molecular mass was calculated using the OMNISEC (v. 5.1) software package (Malvern). Biolayer interferometry (BLI). The binding affinities of IZUMO1 to JUNO were measured by biolayer interferometry using a single-channel BLItz instrument (Pall FortéBio), based on protocols previously described 30 . Briefly, purified wild-type or mutant JUNO in PBS buffer was biotinylated using the EZ link sulfo-NHS-LC-biotinylation kit (Thermo Pierce), according to the manufacturer's instructions. Excess biotin reagent was removed by overnight dialysis in PBS. All streptavidin-coated (SA) biosensors were hydrated in BLI rehydration buffer (PBS, 0.5 mg ml and immobilized onto a SA biosensor for 90 s. Multiple concentrations of wild-type or mutant IZUMO1 (analyte) were prepared in BLI kinetics buffer and association to IZUMO1 was measured over 90 s at 20 °C. Subsequently, the SA biosensor was immersed into BLI kinetics buffer for 90 s to dissociate the analyte. All experiments were performed in triplicate. Two negative controls were performed: BSA and BLI kinetics buffer only against SA biosensors loaded with biotinylated bait to detect non-specific binding. The data were analysed and sensorgrams were step corrected, reference corrected and fit globally to a 1:1 binding model. The equilibrium dissociation constant (K d ), association (k a ) and dissociation (k d ) rate constants and their associated standard errors were calculated using BLItz Pro data analysis (v. 1.1.0.16) software. Surface plasmon resonance (SPR). The affinities and kinetics of wild-type IZUMO1 binding to wild-type JUNO were assessed by SPR on a Biosensing Instruments BI-4000 system at 20 °C using a CM-dextran sensor chip. Prior to immobilization, pH scouting between pH 4.5 and 6.5 was performed to identify the optimal pH for immobilization. Wild-type JUNO 20-228 was immobilized using a coupling buffer containing 10 mM sodium acetate pH 5.0 onto one of two flow channels using the manufacturer's standard amine-coupling protocol. Association of the wild-type IZUMO1 analyte (0.75 μ M, 0.5 μ M, 0.375 μ M, 0.25 μ M, 0.188 μ M, 0.125 μ M, 0.0937 μ M and 0 μ M) was measured at a flow rate of 50 μ l min −1 for 90 s. The second flow cell, containing no bait, was injected with PBS buffer in a serial flow and used as a reference. Subsequently, PBS buffer was injected at a flow rate of 50 μ l min −1 over 180 s to dissociate wild-type IZUMO1 . The cells were regenerated between two analyte runs using the rapid injection protocol involving 8 cycles of 20-μ l injections of 0.01 M NaOH-acetate pH 9.0 followed by an equal volume of 1× PBS. Measurements were performed in triplicate. The resulting SPR sensorgrams were corrected with the reference and blank (0-μ M analyte) curves, and fitted globally with a 1:1 Langmuir binding model using BI-Data Analysis and BI-Kinetic Analysis SPR software. Crystallization and X-ray data collection. Purified IZUMO1 , IZUMO1 , JUNO , and the IZUMO1 22-254 -JUNO 20-228 complex were concentrated to 10 mg ml
. All crystallization trials were performed at 22 °C by sitting drop vapour diffusion (300 nl protein and 300 nl mother liquor) in 96-well low profile Intelliplates (Art Robbins) using an Oryx8 protein crystallization robot (Douglas Instruments). IZUMO1 22-254 and IZUMO1 . Initial sparse matrix screening of IZUMO1 and IZUMO1 constructs identified needle-shaped crystals in multiple conditions. IZUMO1 and IZUMO1 22-268 crystals were manually optimized in 48-well MRC Maxi crystallization plates using 2-μ l sitting drops. Larger needle-shaped IZUMO1 22-254 crystals appeared the next day and reached a maximum length of ~ 250 μ m within 3-4 days in 0.07 M sodium acetate (pH 4.6), 5.6% (w/v) PEG 4000 and 30% (v/v) glycerol. Larger IZUMO1 22-268 crystals were more difficult to obtain and required further optimization using random microseed matrix screening (rMMS) with Oryx8 (ref. 31) . rMMS led to thicker needle crystals in 0.085 M HEPES sodium salt (pH 7.5), 8.5% (v/v) isopropanol, 17% (w/v) PEG 4000 and 15% (v/v) glycerol. These crystals reached a final length of ~ 200 μ m within 4-5 days. All crystals were cryoprotected and flash-cooled in liquid nitrogen. IZUMO1 and IZUMO1 crystals diffracted to Bragg spacings of 3.1 Å and 2.9 Å, respectively, and data sets were remotely collected at the Canadian Light Source (CLS) 08ID-1 beamline (Supplementary Fig. 8 ). JUNO . Rod-shaped JUNO 20-228 crystals were grown in 0.02 M magnesium chloride, 0.1 M HEPES sodium salt (pH 7.5), 22% (w/v) polyacrylic acid 5100. Crystals typically appeared after 3-4 days and reached full size in 1 week. The mother liquor supplemented with increasing amounts of sucrose (up to 30% (w/v) in final solution) was used as a cryoprotectant before being rapidly cooled in liquid nitrogen. JUNO crystals readily produced Bragg reflections at better than 2.0 Å resolution on a Rigaku FR-E Superbright X-ray generator and Saturn A200 HD CCD detector (Rigaku Corp.), and a 1.8 Å resolution data set was collected at the Structural Genomics Consortium X-ray diffraction facility ( Supplementary Fig. 8 ). IZUMO1 22-254 -JUNO 20-228 complex. Crystals of the protein complex were grown in sitting drops containing equal volumes (1 μ l) of purified protein and crystallant (0.1 M MES (pH 6.5), 20% (w/v) PEG 4000 and 0.6 M NaCl). Crystals were observed after 3 days and matured to full size within a week. Crystals were cryoprotected by sequential soaking in mother liquor with 5%, 10%, 20% and 30% (w/v) sucrose. Crystals were directly immersed into liquid nitrogen and screened at the CLS beamline 08ID-1. A data set was collected from a single IZUMO1 -JUNO 20-228 complex crystal diffracting to 2.4 Å resolution (Supplementary Fig. 9 ).
Structure determination and refinement. All diffraction data were integrated and reduced with the XDS program package 32 and scaled using Aimless 33 from the CCP4 program suite. Crystallographic data collection and final refinement statistics are presented in Supplementary Table 1 . JUNO . The structure of JUNO was determined by molecular replacement with Phaser 34 using human folate receptor-α (PDB ID: 4LRH) as the search model. Initial characterization of the JUNO 20-228 X-ray data using phenix.xtriage 35 and DETWIN 36 indicated translational pseudosymmetry 37 (TPS) and near-perfect merohedral twinning 38 with an estimated twin fraction of 0.45 ( Supplementary  Fig. 8 ). The twinning fraction was calculated from the cumulative distribution of H 39 and Britton plots 40 , with the twin fractions related by the twin law k, h, − l. It was necessary to apply the twin law throughout the refinement to further refine the JUNO 20-228 structure using phenix.refine and the 4HB domain of IZUMO1 . The poly-alanine chain of the IZUMO1 was initially traced by a combination of phenix. autobuild 42 and manual building with Coot 43 . Validation of proper sequence registry was confirmed by locating the sulfur anomalous signals from methionine and cysteine residues. Multi-crystal sulfur anomalous data were collected on native IZUMO1 22-254 -JUNO 20-228 complex crystals. The X-ray beam was focused to 50 μ m and the sulfur anomalous signal was measured at a wavelength of 1.7712 Å using a MarMosaic MX300 CCD detector (Rayonix). All crystals were rod-shaped and > 400 μ m in length, thus allowing us to translate along the rotation axis to expose a fresh undamaged part of the crystal. 360° of data with a rotation angle of 1.0° per frame were collected for each set before translating to a new part of the crystal. Each data set was processed individually with anomalous signal using XDS 32 . Twenty-four data sets with R meas < 10% were merged together using XSCALE 32 and converted to CCP4 data format using XDSCONV 32 , F2MTZ and CAD 36 . The overall R merge and anomalous multiplicity for the merged data set to 2.8 Å resolution were 9.9% and 89.6, respectively. An anomalous difference Fourier electron density map was calculated using PHENIX 35 and confirms the correct location for all 38 protein sulfur sites ( Supplementary Fig. 9 ). IZUMO1 22-254 and IZUMO1 . The structures of IZUMO1 and IZUMO1 were determined by molecular replacement. An initial molecular replacement search using the refined IZUMO1 22-254 structure from the IZUMO1 22-254 -JUNO 20-228 complex failed, probably because of conformational changes between the 4HB and Ig-like domains. A molecular replacement search was performed first using the IZUMO1 Ig-like domain (residues 167-254) followed by a second molecular replacement search using the 4HB and hinge regions (residues 22-166). Clear solutions were identified for both sections in IZUMO1 and IZUMO1 .
All structures were manually rebuilt using Coot 43 and refined using phenix. refine 41 . No non-crystallographic (NCS) symmetry restraints were employed except in the case of JUNO , where a four-fold NCS was applied. All β -strands and α -helices were real-space refined with torsional secondary structural restraints using Coot. Torsion-angle simulated annealing refinement, starting at 5,000 K, with individual atomic displacement and Translation/Liberation/Screw (TLS) groups was carried out using Phenix. Owing to the lower resolutions of the IZUMO1 and IZUMO1 data, these structures were refined with grouped B-factor refinement. Calculation of annealed 2| F o | − | F c | composite omit maps 44 helped minimize model bias during rebuilding. Validation and structure analysis. The stereochemical quality of all the refined models was validated using MolProbity 45 , PROCHECK 46 and Coot
43
. No residues were identified in disallowed regions of the Ramachandran plot. Moreover, the R values, B-factors, and r.m.s.d. bond lengths and angles of all structural models are consistent with other deposited structures determined at similar resolutions, as validated by polygon.phenix 35 . All structural representations were prepared using PyMOL (v. 1.7.4 Schrödinger, LLC.) SAXS data collection and reconstruction. SAXS provides medium-resolution visualization of global structural conformational changes in solution. SAXS experiments were performed by mail-in SAXS on beamline 12.3.1 (SIBYLS) at the Advanced Light Source. Various protein concentrations of tagcleaved, deglycosylated wild-type and mutant IZUMO1 , JUNO and IZUMO1 -JUNO complexes, along with matching buffer obtained from SEC (10 mM Tris-HCl (pH 8.0), 150 mM NaCl and 2% (v/v) glycerol), were loaded into a 96-well PCR plate (Axygen) and stored at 4 °C before data collection. Samples were loaded into the SAXS sample cell using a Hamilton syringe robot. For the wild-type IZUMO1 , JUNO and IZUMO1 22-254 -JUNO complex, data were collected at a wavelength (λ) of 1.0 Å using a MarCCD 165 detector (Rayonix) positioned at a distance of 1.5 m, resulting in scattering vector q of 0.01 Å −1 < q < 0.32 Å −1 (where q = 4π sin(θ/2)/λ and θ is the scattering angle). Each data set was recorded at 283 K in a succession of three X-ray exposures of 0.5, 1, 2 and 5 s. For the mutant IZUMO1 22-254 -JUNO complexes, data were collected at 1.0 Å wavelength using a Pilatus3 × 2 M detector (Dectris) (0.01 Å −1 < q < 0.55 Å −1 ). Data for the mutant IZUMO1 22-254 -JUNO complexes were recorded in a time slicing mode of 0.5-s exposures over 15 s (30 frames per sample). Data for buffer blanks were collected before each protein image and subsequently buffer subtracted. Sample radiation damage was assessed by overlaying short and long exposures and detecting for any shifts in the scattering curves using the program SCATTER 47 . Concentration and aggregation effects were detected by comparing the lowest scattering angles for each of the protein samples. Fits to the Guinier region were made using autoRg. To maximize the signal-to-noise ratio, the SAXS scattering curve at the highest concentration that is free of interparticle interference was used for subsequent analysis. The characteristic real-space distance distribution function, P(r), was determined from the scattering data using an indirect Fourier transformation and the maximum dimension, D max 48 . All ab initio reconstructions of molecular envelopes from SAXS data were performed using the program DAMMIN 49 . Twenty-three DAMMIN models were superimposed and averaged by the program DAMAVER 50 to obtain a consensus averaged structure. Alignment of the SAXS reconstructions with the final refined crystal structures was performed using Chimera 51 . Deuterium exchange mass spectrometry (DXMS). DXMS, which measures kinetics of backbone amide solvent exchange, provides local residue-level conformational dynamics. Prior to performing deuterium exchange experiments, the optimal proteolysis conditions were established as previously described 52, 53 to maximize peptide sequence coverage of tag-cleaved, deglycosylated IZUMO1 and JUNO . Briefly, 1 μ l of diluted protein stock solution (2 mg ml −1 in 10 mM Tris (pH 7.2), 150 mM NaCl) was mixed with 5 μ l quench buffer (6.4 M GuHCl and 1.0 M TCEP in 0.8% (v/v) formic acid, 16.6% (v/v) glycerol). After incubating on ice for various times (2, 5, 10, 15 and 30 min), the quenched samples were mixed with 24 μ l dilution buffer (0.8% (v/v) formic acid, 16.6% (v/v) glycerol) and then subjected to proteolysis and LC-MS analysis. The IZUMO1 22-254 -JUNO 20-228 complex was formed by mixing IZUMO1 and JUNO 20-228 at 1:1.2 or 1.2:1 molar ratios and incubating the samples at 22 °C for 2 h. Deuterium exchange was initiated by mixing 3.5 μ l of protein stock solution (IZUMO1 , IZUMO1 22-254 -JUNO , JUNO or JUNO 20-228 -IZUMO1 ) with 7 μ l D 2 O buffer (8.3 mM Tris (pH 7.2), 150 mM NaCl in D 2 O, pD read 7.2) and incubating at 0 °C for 10, 100, 1000, 10,000 and 100,000 s. At indicated times, 2.1 μ l of exchange samples were added to 10.5 μ l quench solution to stop the D 2 O exchange reaction. After 5 min (IZUMO1 or IZUMO1 22- 254 -JUNO 20-228 ) or 10 min (JUNO or JUNO 20-228 -IZUMO1 ) incubation on ice, quenched samples were diluted by addition of 48 μ l of icecold dilution buffer, and then immediately frozen on dry ice and stored at − 80 °C. The non-deuterated control samples and equilibrium-deuterated control samples were also prepared by mixing protein with H 2 O buffer (8.3 mM Tris (pH 7.2), 150 mM NaCl in H 2 O) and equilibrium-deuterated buffer (0.8% (v/v) formic acid in 99.9% D 2 O) 54 . The frozen samples were then thawed at 5 °C and passed over an immobilized pepsin column (16-μ l bed volume) at a flow rate of 20 μ l min −1 . The resulting peptides were collected on a C 18 trap for desalting and separated by a Magic AQ C18 reverse phase column (Michrom BioResources) using a linear gradient of acetonitrile from 6.4% to 38.4% over 30 min. MS analysis was performed using the OrbiTrap Elite Mass Spectrometer (ThermoFisher Scientific), with a capillary temperature of 200 °C. Data were acquired in both data-dependent MS/MS mode and MS1 profile mode, and the data were analysed by Proteome Discoverer software and DXMS Explorer 55 (Sierra Analytics Inc.).
